" class="no-js "lang="en-US"> GTP Bioways - Medtech Alert
Wednesday, July 16, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
GTP Bioways | Pharmtech Focus

GTP Bioways

About GTP Bioways

GTP Bioways

GTP Bioways is an expert and fast-growing contract development and manufacturing organisation (CDMO) offering uniquely customised process development and manufacturing services for biologics, antibody-drug conjugates and nanodrugs.
With cutting-edge facilities located in France, GTP Bioways supports biopharma companies in bringing their innovative molecules from research to clinic and market.

Related Story

Industry News

 GTP Bioways Invests €12M in Two GMP Biopharmaceutical Production Units | Pharmtech Focus

GTP Bioways Invests €12M in Two GMP Biopharmaceutical Production Units

October 22 2021

GTP Bioways, a CDMO (Contract Development and Manufacturing Organization) specializing in the production of biotherapies […]